cas 843644-23-5|| where to buy 6,8-difluoro-3,4-dihydronaphthalen-2(1H)-one

Nom du produit:6,8-difluoro-3,4-dihydronaphthalen-2(1H)-one

IUPAC Name:6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-one

Unité d'emballage	Stock disponible	Prix($)
CM124434-1g	in stock	ƐȖ
CM124434-5g	in stock	ȤǠȅ
CM124434-10g	in stock	ǆǆȅ
CM124434-25g	in stock	ƐȖȤ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 843644-23-5 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:843644-23-5; Formule moléculaire:C10H8F2O; Point de fusion:-; Code SMILES:O=C1CC2=C(C=C(F)C=C2F)CC1; Densité:

: Numéro de catalogue:CM124434; Poids moléculaire:182.17; Point d'ébullition:; N° Mdl:MFCD05663016; Stockage:

: Naphthalenes; Naphthalene is a hydrocarbon produced by the distillation of coal tar and is an aromatic white crystalline substance. Naphthalene is the most abundant component in coal tar. It is used as an insect repellant and insect fumigant. The compound is used in the manufacture of celluloid, dyes, hydrogenated naphthalenes, oil fumes, smokeless powders and synthetic resins.

: Ogsiveo; The FDA has approved Ogsiveo (Nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. The FDA approval of Ogsiveo is based on the results from the Phase 3 DeFi trial. The results showed that Ogsiveo met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). Ogsiveo is an oral, selective, small molecule gamma secretase inhibitorγ. Gamma secretase cleaves multiple transmembrane proteins, including Notch, that are believed to play a role in activating pathways that contribute to growth of desmoid and ovarian granulosa cell tumors.